Jazz Pharmaceuticals

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Retrieved on: 
Tuesday, April 9, 2024
Survival, Immunotherapy, Neuroblastoma, Patient, Journal, EFS, Acquisition, Jazz Pharmaceuticals, Cancer, Radiation, Haematopoietic system, Pharmaceutical industry

This will be Essential’s first clinical development-stage asset and is targeted at addressing significant unmet needs in paediatric oncology patients.

Key Points: 
  • This will be Essential’s first clinical development-stage asset and is targeted at addressing significant unmet needs in paediatric oncology patients.
  • Simon Ball, CEO and co-founder of Renaissance Pharma, who has significant scientific and commercial expertise within the space, will continue to work with Essential Pharma on Hu14.18’s development, as will many of the Renaissance Pharma team.
  • Approximately half of all neuroblastoma patients have high risk (HRNB) disease which has an overall survival of ~50% over five years23.
  • Essential Pharma will be responsible for clinical development and defining the optimal route for regulatory approval and eventual commercial launch of Hu14.18.

Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sleep, Monitor Deloitte, Growth, Patient, Acquisition, Cancer, Spacecraft, Senior, Therapy, Bain, Partner, GW Pharmaceuticals, ADC, Bain & Company, Corporate development, Jazz Pharmaceuticals, Pharmaceutical industry

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
  • “I am delighted to welcome George to the Mythic team,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
  • Prior to that, Dr. Eliades spent over 20 years at Bain & Company and Monitor Group, advising biotech clients in corporate strategy, M&A, growth and digital-driven transformations.
  • Dr. Eliades stated, “I’m incredibly excited to join Mythic and work toward improving outcomes for more cancer patients through our pipeline of innovative ADCs.

SAPA-GP Hosted the 2024 Annual Conference Highlighting the Innovating Biopharma Frontier

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Health informatics, Informatics, COVID 19, McKinsey & Company, COVID, Conference, Data science, Spark Therapeutics, AI, Volunteering, Section, MBA, Yale School of Medicine, Therapy, Process, Drug development, Yale school, Multimedia, Proposition, Jazz Pharmaceuticals

On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.

Key Points: 
  • On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.
  • Fangning Zhang, MBA, Partner at McKinsey & Company, delivered the conference opening keynote speech “Path towards Value Creation – China Biopharma Innovation Trends”.
  • “Our conference has been very successful in capturing the latest trends foretelling the direction of biopharma industry.
  • The 2024 SAPA-GP Annual Conference was a great gathering of life scientists, pharmaceutical experts, and business leaders from diverse backgrounds, experiences, and accomplishments.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

TSC Alliance® to Host 23rd Annual Comedy for a Cure® on April 14 in Los Angeles

Retrieved on: 
Friday, March 15, 2024
TSC, Jim, Learning, Parks and Recreation, Disease, Patient, The King of Queens, Neoplasm, DSM-IV codes, Research, Courage, Vibiana, The Tonight Show, Ovation, Movement disorder, Jazz, Jazz Pharmaceuticals, Comedy, Cure, Pharmaceutical industry

LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.

Key Points: 
  • LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.
  • "Every year, Comedy for Cure helps our organization raise significant funds to further TSC research, offer expanded support programs and increase awareness about the disease," said Kari Luther Rosbeck, TSC Alliance President & CEO.
  • "Over the years, this signature event has raised almost $6 million cumulatively to help improve the lives of everyone affected by TSC."
  • Comedy for a Cure also offers the opportunity to pay tribute to those who have made significant impacts in the right against TSC.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
GEA, Patient, Breast cancer, Interest, Jazz Pharmaceuticals, Cancer, BTC, Cholangiocarcinoma

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.

Key Points: 
  • DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
  • ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
  • Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
GEA, Patient, Breast cancer, Interest, Jazz Pharmaceuticals, Cancer, BTC, Cholangiocarcinoma

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.

Key Points: 
  • DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
  • ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
  • Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

NATIONAL SLEEP FOUNDATION SAYS TEENS' SLEEP HEALTH AND MENTAL HEALTH STRONGLY LINKED

Retrieved on: 
Thursday, March 7, 2024
Mental health, Doctor of Philosophy, American Heart Association, Jazz Pharmaceuticals, National Sleep Foundation, NSF, Sleep, PHQ, Grammatical mood, Mental disorder, Health, Samsung Health, Suicide, Organization, Student, Depression, Knowledge, Congress, Homelessness, Clifford Whittingham Beers, National Alliance

WASHINGTON, March 7, 2024 /PRNewswire/ -- To kick off Sleep Awareness Week® 2024 (March 10-16), the National Sleep Foundation (NSF) released new findings from their annual Sleep in America® Poll. This year focused on exploring the important connection between sleep health and mental health in American teens. Results from this first-of-its-kind study in teens found that healthy sleep behaviors are closely linked to mental health in teens. In fact, nearly 80% of teens who earn a grade of 'B' or higher for practicing healthy sleep behaviors are also free of significant depressive symptoms.

Key Points: 
  • This year focused on exploring the important connection between sleep health and mental health in American teens.
  • Results from this first-of-its-kind study in teens found that healthy sleep behaviors are closely linked to mental health in teens.
  • Importantly, these results expand the base of knowledge about the connection between sleep health and mental health in the American public.
  • Also during Sleep Awareness Week 2024, NSF will be holding a Congressional Briefing entitled Sleep Health is Mental Health, on Wednesday, March 13.

Debbie's Dream Foundation: Curing Stomach Cancer Hosts a Historic 12th Annual Stomach Cancer Capitol Hill Advocacy Day in 2024

Retrieved on: 
Tuesday, March 5, 2024
Stomach cancer, Bangladesh Technical Education Board, Caregiver, Origin, Jazz Pharmaceuticals, News, Federation, Fiscal year, National Cancer Institute, DDF, Merck & Co., Patient, Congress, FY, Research, Pharmaceutical industry

WASHINGTON, March 5, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer celebrated a historic turnout for its 12th Annual Stomach Cancer Capitol Hill Advocacy Day hosted February 5-7, 2024, in Washington, DC. On the morning of February 6, just as the world learned of country music legend Toby Keith's passing from stomach cancer, nearly 150 advocates demonstrated resilience and determination on Capitol Hill, attending 221 scheduled meetings with lawmakers. The advocates passionately conveyed critical asks, urging Congress to pass the Fiscal Year (FY) 2024 spending bills to prevent disruptions in essential research funding, keep stomach cancer on the Peer Reviewed Cancer Research Program (PRCRP) list for FY 2025, and increase FY 2025 funding to the National Institutes of Health and National Cancer Institute.

Key Points: 
  • WASHINGTON, March 5, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer celebrated a historic turnout for its 12th Annual Stomach Cancer Capitol Hill Advocacy Day hosted February 5-7, 2024, in Washington, DC.
  • Their unwavering support in Congress has significantly raised stomach cancer awareness and has led to increased federal research dollars for stomach cancer.
  • Over the years, DDF's advocacy efforts have resulted in $34.4 million dedicated to stomach cancer research through the PRCRP to date.
  • DDF expresses heartfelt gratitude to all advocates, sponsors, and supporters who contributed to the success of the 12th Annual Stomach Cancer Capitol Hill Advocacy Day.